Condition: Billiary Track Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
This description comes directly from the study's public registry record.
Colleen Apostal, RN · 410-614-3644 · GIClinicalTrials@jhmi.edu
Always discuss trial participation with your own doctor first.
| SKCCC Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06001658